Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

Cyclophosphamide 73Rituximab 59Specimen Handling 49Biopsy 42Doxorubicin 41Vincristine 40Magnetic Resonance Spectroscopy 39Prednisone 36venetoclax 28obinutuzumab 27fludarabine 26ibrutinib 22Methotrexate 22Dexamethasone 21Cytarabine 21Lenalidomide 20blinatumomab 19Etoposide 19merphos 17zanubrutinib 16acalabrutinib 16prednylidene 15fludarabine phosphate 15deltacortene 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13CT-P10 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Procarbazine × Lymphoid × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡